At the American Academy of Ophthalmology's annual conference, Rona Z. Silkiss, MD, FACS, an oculoplastic surgeon and owner of Silkiss Eye Surgery, dived into how biologic therapies can be used to treat thyroid eye disease and what can be done to ensure patients have access to these treatments.
Transcript
How has the use of biologics for thyroid eye disease grown over time and how is research in this space expected to develop?
Silkiss: It is a very exciting time to be treating thyroid eye disease. The notion of using a biologic began in 2009 with Laszlo Hegedus, who suggested that we try utilizing rituximab for thyroid eye disease. Since that time, rituximab, tocilizumab, and teprotumumab [teprotumumab-trbw] have been used in the United States for thyroid eye disease. Teprotumumab, of course, is the only drug that's currently FDA-approved for this indication. Rituximab and tocilizumab have been studied in clinical trials extensively and have been utilized as well.
But the space is just beginning to open up with great interest from the pharmaceutical industry and there are a dozen or more similar type of drugs in the pipeline. They could be various forms of IGF-1R [insulin-like growth factor type 1 receptor] inhibitors, an FcRn [neonatal Fc receptor ] inhibitor, TSHR [thyrotropin receptor] inhibitor, and IL-17 [interleukin 17] and IL-11 inhibitors, etc. I think the future is going to be filled with a lot of exciting developments in this field.
What can health care professionals in ophthalmology do to ease new patients and their caregivers into using biologic therapies, especially as “biologic” is not a household term?
Silkiss: Well, the first thing is that as a health care provider, we want to provide the absolute best health care to our patients. And by that I mean that we want to diagnose our patients correctly, and give them the full array of therapeutic modalities that they can choose from. And specifically, not only provide informed consent, but incorporate their comorbidities into the decision making.
So, for a young woman that might wish to become pregnant, she would not want to use certain biologics if she developed thyroid eye disease because of the risk to a pregnancy. If someone were a diabetic, they may choose not used a biologic, etc. So, this is a complex space. And though each of these biologics has great promise and therapeutic advantage, in some respects, they also come with adverse events, and we need to carefully weigh what the word "efficacy" means for the individual patient.
What more needs to be done to ensure that patients with thyroid eye disease and other ophthalmic conditions have adequate access to biologic therapies?
Silkiss: Well, we're hoping that the biologic space becomes very crowded, so that the cost of treatment decreases significantly so that we can provide access and equity to our patient population, not only in the United States, but around the world. Currently, the FDA-approved biologic is quite expensive, and that poses a challenge for providing this for patient care.
My hope is that as the space becomes more competitive, that the price will adhere to market forces and will decrease accordingly and that there will be a wider range of biologics to treat patients that have various stages of the disease and also, we can be selective in terms of providing exactly the right biologic for the patient depending on their state of disease and comorbidities.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More